- News Room
- HKSTP Partner Company Cellomics Secured Strategic Investment from China Taiping’s Innovation and Technology Venture Fund
(Hong Kong, 12 July 2023) – Hong Kong Science and Technology Parks Corporation (HKSTP) congratulates its partner company, Cellomics Holdings Limited, for receiving a strategic equity investment from Taiping Hong Kong Insurance Innovation and Technology Venture Fund (Taiping HK I&T Fund) under China Taiping Insurance Group Co., Ltd. (China Taiping), and establishing a strategic partnership with Taiping General Insurance Co., Ltd. Shenzhen Branch (Taiping General Insurance), a subsidiary of China Taiping. This collaboration clearly demonstrates Hong Kong's position as a fast- growing biomedical technology hub.
Cellomics announced recently that it has secured a strategic equity investment from Taiping HK I&T Fund. The funding provides momentum for Cellomics to accelerate the company's innovative product pipelines and expand the commercial capabilities. The investment in Cellomics is an example of China Taiping’s mission to promote the development of innovation and technology in the Guangdong-Hong Kong-Macao Greater Bay Area, and to better serve the “Health China 2030” strategy to improve the people's livelihood.
Meanwhile, Cellomics established a strategic partnership with Taiping General Insurance to jointly develop health service products. Through the new model of "service + insurance", the two companies co-launched the "Taiping-Cellomics" health service plan, integrating innovative technology, insurance protection, medical services and health management, to provide more comprehensive, efficient, and advanced health care services for better serving the community, and to contribute to the development of the Guangdong-Hong Kong-Macao Greater Bay Area.
Cellomics Holdings Limited is a biotech company rooted in Hong Kong Science Park and developing rapidly in recent years. It is focused on the development and commercialization of liquid biopsy products for cancer screening, precision diagnosis, and disease monitoring. Its subsidiary Cellomics
International Limited is supported by HKSTP’s Incu-Bio programme. Incu-Bio provides biotech startups with lab facilities, business support, investment opportunities and financial aid, turning their innovative ideas into market products. Cellomics’ core technology and R&D team come from top international biomedical institutions such as City University of Hong Kong, Tsinghua University, University of Edinburgh, University of Copenhagen, and Baylor College of Medicine. Cellomics develops products and services for early cancer screening, precision diagnosis, and disease monitoring. Its first-generation circulating tumor cell (CTC) sorting instrument and digital PCR instrument have received market approval from NMPA. It also offers the self-developed CTC single-cell sequencing service via its accredited medical laboratory in Shenzhen.
Taiping HK I&T Fund was established by Taiping Financial Holdings Co., Ltd., an overseas investment platform of China Taiping, focusing on medical, health, elderly care, and related technology fields Based in Hong Kong, the Fund is actively investing in high-quality equity projects with long-term investment value and serving the “Health China 2023” national strategy, exploring investment opportunities in the Guangdong-Hong Kong-Macao Greater Bay Area. China Taiping is in the Fortune Global 500 list for five consecutive years.
Photo 1: Cellomics and Taiping General Insurance established a strategic partnership to jointly launch the "Taiping-Cellomics" health service plan. Among those attending the launching ceremony included Ms. Peng Yunping, Deputy General Manager of Taiping General Insurance (fourth from right), Professor Michael Yang, Co-founder of Cellomics and Senior Vice President of City University of Hong Kong (fifth from right), Mr. Xu Shaowu, General Manager of Taiping General Insurance (Shenzhen) (fifth from left), Ms. Jenny Zhang, CEO of Cellomics (Shenzhen) (third from right), Dr. Henry Zou, Co- founder and Vice President of Cellomics (first from right).